Myriad Settles Breast Cancer Test Patent Suit With Ambry
Ambry Genetics Corp. said Monday it has reached a settlement agreement with Myriad Genetics Inc., which had accused the genetic testing company of infringing its patents on breast cancer tests, several...To view the full article, register now.
Already a subscriber? Click here to view full article